Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a
- 4 May 1989
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 320 (18), 1197-1200
- https://doi.org/10.1056/nejm198905043201807
Abstract
PULMONARY hemangiomatosis is a rare, fatal disorder characterized by diffuse microvascular proliferation within the lung. The disease most often affects children and young adults and usually progresses rapidly, causing death from pulmonary hypertension or bleeding. Most cases have been diagnosed at autopsy. Corticosteroids and cyclophosphamide have been used for this condition, but no successful therapy has been described.We describe a patient with pulmonary hemangiomatosis who presented with digital clubbing and bilateral interstitial pulmonary disease. After a decline in the patient's exercise tolerance, therapy with interferon alfa-2a was initiated and has been continued for 14 months at the time of . . .This publication has 21 references indexed in Scilit:
- Familial Pulmonary Capillary Hemangiomatosis Resulting in Primary Pulmonary HypertensionAnnals of Internal Medicine, 1988
- Thoracic Hemangiomatosis Masquerading as Interstitial Lung DiseaseChest, 1988
- Inhibition of endothelial cell proliferation by gamma-interferon.The Journal of cell biology, 1987
- Pulmonary capillary hemangiomatosisHuman Pathology, 1986
- The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle eventsExperimental Cell Research, 1985
- OPENING REMARKSAnnals of the New York Academy of Sciences, 1980
- Inhibition of Cell Motility by InterferonScience, 1980
- Capillary haemangiomatosis of the lungsHistopathology, 1978
- Diffuse Pulmonary HemangiomatosisRadiology, 1978
- Pulmonary veno-occlusive diseaseThe American Journal of Surgical Pathology, 1977